Drug transporters in breast cancer: response to anthracyclines and taxanes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Drug transporters in breast cancer : response to anthracyclines and taxanes. / Kümler, Iben; Stenvang, Jan; Moreira, José; Brünner, Nils; Nielsen, Dorte Lisbet.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 9, 09.2015, p. 1075-1092.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kümler, I, Stenvang, J, Moreira, J, Brünner, N & Nielsen, DL 2015, 'Drug transporters in breast cancer: response to anthracyclines and taxanes', Expert Review of Anticancer Therapy, vol. 15, no. 9, pp. 1075-1092. https://doi.org/10.1586/14737140.2015.1067610

APA

Kümler, I., Stenvang, J., Moreira, J., Brünner, N., & Nielsen, D. L. (2015). Drug transporters in breast cancer: response to anthracyclines and taxanes. Expert Review of Anticancer Therapy, 15(9), 1075-1092. https://doi.org/10.1586/14737140.2015.1067610

Vancouver

Kümler I, Stenvang J, Moreira J, Brünner N, Nielsen DL. Drug transporters in breast cancer: response to anthracyclines and taxanes. Expert Review of Anticancer Therapy. 2015 Sep;15(9):1075-1092. https://doi.org/10.1586/14737140.2015.1067610

Author

Kümler, Iben ; Stenvang, Jan ; Moreira, José ; Brünner, Nils ; Nielsen, Dorte Lisbet. / Drug transporters in breast cancer : response to anthracyclines and taxanes. In: Expert Review of Anticancer Therapy. 2015 ; Vol. 15, No. 9. pp. 1075-1092.

Bibtex

@article{a1265c0696284ddfa7f532f6d2421e9f,
title = "Drug transporters in breast cancer: response to anthracyclines and taxanes",
abstract = "Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.",
author = "Iben K{\"u}mler and Jan Stenvang and Jos{\'e} Moreira and Nils Br{\"u}nner and Nielsen, {Dorte Lisbet}",
year = "2015",
month = sep,
doi = "10.1586/14737140.2015.1067610",
language = "English",
volume = "15",
pages = "1075--1092",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor & Francis",
number = "9",

}

RIS

TY - JOUR

T1 - Drug transporters in breast cancer

T2 - response to anthracyclines and taxanes

AU - Kümler, Iben

AU - Stenvang, Jan

AU - Moreira, José

AU - Brünner, Nils

AU - Nielsen, Dorte Lisbet

PY - 2015/9

Y1 - 2015/9

N2 - Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.

AB - Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.

U2 - 10.1586/14737140.2015.1067610

DO - 10.1586/14737140.2015.1067610

M3 - Journal article

C2 - 26313418

VL - 15

SP - 1075

EP - 1092

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 9

ER -

ID: 145247652